» Articles » PMID: 38178870

Antioxidant Mechanisms of Mesenchymal Stem Cells and Their Therapeutic Potential in Vitiligo

Overview
Specialty Cell Biology
Date 2024 Jan 5
PMID 38178870
Authors
Affiliations
Soon will be listed here.
Abstract

Vitiligo is a skin pigmentation disorder caused by melanocyte damage or abnormal function. Reac-tive oxygen species Reactive oxygen species can cause oxidative stress damage to melanocytes, which in turn induces vitiligo. Traditional treatments such as phototherapy, drugs, and other methods of treatment are long and result in frequent recurrences. Currently, mesenchymal stem cells (MSCs) are widely used in the research of various disease treatments due to their excellent paracrine effects, making them a promising immunoregulatory and tissue repair strategy. Furthermore, an increasing body of evi-dence suggests that utilizing the paracrine functions of MSCs can downregulate oxidative stress in the testes, liver, kidneys, and other affected organs in animal models of certain diseases. Addition-ally, MSCs can help create a microenvironment that promotes tissue repair and regeneration in are-as with oxidative stress damage, improving the disordered state of the injured site. In this article, we review the pathogenesis of oxidative stress in vitiligo and promising strategies for its treatment.

References
1.
Uccelli A, Pistoia V, Moretta L . Mesenchymal stem cells: a new strategy for immunosuppression?. Trends Immunol. 2007; 28(5):219-26. DOI: 10.1016/j.it.2007.03.001. View

2.
Tong K, Katoh Y, Kusunoki H, Itoh K, Tanaka T, Yamamoto M . Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol Cell Biol. 2006; 26(8):2887-900. PMC: 1446969. DOI: 10.1128/MCB.26.8.2887-2900.2006. View

3.
Diotallevi F, Gioacchini H, De Simoni E, Marani A, Candelora M, Paolinelli M . Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art. Int J Mol Sci. 2023; 24(5). PMC: 10003418. DOI: 10.3390/ijms24054910. View

4.
Boor P, Floege J . Chronic kidney disease growth factors in renal fibrosis. Clin Exp Pharmacol Physiol. 2011; 38(7):441-50. DOI: 10.1111/j.1440-1681.2011.05487.x. View

5.
Ni S, Wang D, Qiu X, Pang L, Song Z, Guo K . Bone marrow mesenchymal stem cells protect against bleomycin-induced pulmonary fibrosis in rat by activating Nrf2 signaling. Int J Clin Exp Pathol. 2015; 8(7):7752-61. PMC: 4555668. View